Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Relapsed/Refractory Hematologic Malignancies and Severe Hepatic or Renal Impairment or Normal Hepatic and Renal Function

NCT07923071 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07923071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Relapsed/Refractory Hematologic Malignancies and Severe Hepatic or Renal Impairment or Normal Hepatic and Renal Function
Lead sponsor
Syndax Pharmaceuticals
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
January 31, 2032
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, refractory leukemia, relapsed leukemia, relapsed/refractory (r/r) hematologic malignancies

Arms

As registered; 3 arms.

  • Group A: Severe Hepatic Impairment ExperimentalRevumenib

    PK evaluation Period: Participants will receive a single Reduced Dose A of revumenib on Day 1.

    Optional Treatment Period: If the Investigator believes it is in the best clinical interest of the participant, the participant may start the Optional Treatment Period immediately after completing the PK Evaluation Period on Study Day 2.

    Participants who start the Optional Treatment Period will receive revumenib twice daily (Q12h), which may be continued for up to 2 years.

  • Group B: Severe Renal Impairment ExperimentalRevumenib

    PK evaluation Period: Participants will receive a single Reduced Dose B of revumenib on Day 1.

    Optional Treatment Period: If the Investigator believes it is in the best clinical interest of the participant, the participant may start the Optional Treatment Period immediately after completing the PK Evaluation Period on Study Day 2.

    Participants who start the Optional Treatment Period will receive revumenib twice daily, which may be continued for up to 2 years.

  • Group C: Normal Hepatic and Renal Function ExperimentalRevumenib

    PK evaluation Period: Participants will receive a single Recommended Dose of revumenib on Day 1.

    Optional Treatment Period: If the Investigator believes it is in the best clinical interest of the participant, the participant may start the Optional Treatment Period immediately after completing the PK Evaluation Period on Study Day 2.

    Participants who start the Optional Treatment Period will receive revumenib twice daily, which may be continued for up to 2 years.

Primary endpoints

Registered primary outcome measures; 6 primary.

  • Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of Revumenib Up to 1 day postdose
  • Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of M1 Up to 1 day postdose
  • Maximum Observed Concentration (Cmax) of Revumenib Up to 1 day postdose
  • Maximum Observed Concentration (Cmax) of M1 Up to 1 day postdose
  • Terminal Elimination Half-Life (t1/2) of Revumenib Up to 1 day postdose

+1 more primary endpoint

Lead sponsor's other trials

Syndax Pharmaceuticals, most recent start first.

Similar trials

Same condition (Leukemia, Biphenotypic, Acute) and phase, most recent start first.